Shaanxi Meibang Pharmaceutical Group Co., Ltd. (605033.SS)
CNY 19.33
(-0.1%)
CNY 19.33
(-0.1%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 577.83 Million CNY | 21.87% |
| 2022 | 474.14 Million CNY | -4.49% |
| 2021 | 496.42 Million CNY | 47.53% |
| 2020 | 336.5 Million CNY | 13.94% |
| 2019 | 295.33 Million CNY | -4.55% |
| 2018 | 309.4 Million CNY | -6.02% |
| 2017 | 329.22 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 543.64 Million CNY | 4.35% |
| 2024 Q3 | 620.2 Million CNY | 14.08% |
| 2024 Q1 | 520.96 Million CNY | -9.84% |
| 2023 Q4 | 577.83 Million CNY | 92.66% |
| 2023 FY | 577.83 Million CNY | 21.87% |
| 2023 Q3 | 299.93 Million CNY | 30.12% |
| 2023 Q2 | 230.5 Million CNY | -18.15% |
| 2023 Q1 | 281.61 Million CNY | -40.6% |
| 2022 Q3 | 538.28 Million CNY | 36.86% |
| 2022 Q2 | 393.3 Million CNY | 1.44% |
| 2022 Q1 | 387.72 Million CNY | -21.9% |
| 2022 FY | 474.14 Million CNY | -4.49% |
| 2022 Q4 | 474.14 Million CNY | -11.92% |
| 2021 Q4 | 496.42 Million CNY | -17.28% |
| 2021 Q3 | 600.15 Million CNY | 121.92% |
| 2021 Q2 | 270.43 Million CNY | 3.96% |
| 2021 FY | 496.42 Million CNY | 47.53% |
| 2021 Q1 | 260.13 Million CNY | -22.69% |
| 2020 FY | 336.5 Million CNY | 13.94% |
| 2020 Q1 | - CNY | 0.0% |
| 2020 Q4 | 336.5 Million CNY | 0.0% |
| 2020 Q2 | 154.97 Million CNY | 0.0% |
| 2019 FY | 295.33 Million CNY | -4.55% |
| 2018 FY | 309.4 Million CNY | -6.02% |
| 2017 FY | 329.22 Million CNY | 0.0% |